Dr. Leyland-Jones Discusses the Phase III HERA Trial
Brian Leyland-Jones, MBBS, PhD
Published Online: Friday, December 7, 2012
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses results from an 8 year follow-up of the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in 5102 women with HER2-postive early-stage breast cancer.
Leyland-Jones believes that the length of time needed to reach the expected 725 events needed to power a survival analysis provides great news for patients with breast cancer. Many believed these results would be available sooner than 8 years. In general, the results for the two arms of the trial were similar, showing no additional benefit for 2 years of trastuzumab. Prior to this trial, Leyland-Jones believed an added benefit would be observed.
The adjusted hazard ratio (HR) for disease free survival for two years versus one of adjuvant trastuzumab was 0.99. The HR for overall survival between the two arms was 1.05. The overlapping of these curves demonstrates no benefit for an additional year of trastuzumab, Leyland-Jones explains.
Managing the side effects associated with mTOR inhibition is a novel endeavor for many breast oncologists. As such, in this segment, the panelists explore the side effects that warrant enhanced awareness and the markers being explore to predict response, in order to avoid unwarranted side effects.
After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.
In this segment, the panelists discuss the combination of novel agents with hormonal therapies. To begin the conversation, the BOLERO-2 trial is explored, which looked at the mTOR inhibitor everolimus as a treatment for patients with metastatic breast cancer.